The GLP-Era: Why This Conversation Matters for Men
GLP-1 receptor agonists, now used by millions of American men, are powerful tools for weight loss, but they come with tradeoffs that matter specifically for men's health: accelerated lean muscle loss, potential testosterone disruption, and metabolic shifts that require intentional countermeasures. Understanding what these drugs take from you, and how to protect against those losses, is the most important health conversation men over 35 should be having right now.
TL;DR
- ~6 million Americans currently use GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound), projected to reach 10 million by 2027.
- Three generations exist: GLP-1 agonists (semaglutide), dual agonists (tirzepatide), and triple agonists (retatrutide in trials).
- Men lose significantly more lean muscle mass during GLP-mediated weight loss than women, 25-40% of total weight lost comes from muscle.
- Testosterone trajectories diverge: some men see improvements with fat loss, others experience drops tied to calorie deficit and muscle loss.
- Protection strategies, targeted nutrition, resistance training, adequate protein, become non-negotiable, not optional.
Why this isn't just another weight-loss trend
Walk into any primary care clinic in 2025 and you'll hear it: Ozempic. Wegovy. Mounjaro. These aren't fringe treatments anymore. By 2024, KFF survey data shows roughly 1 in 8 U.S. adults have used a GLP-1 medication, with industry analyses tracking millions of active prescriptions and that number climbing fast. The category has moved from niche diabetes medication to one of the fastest-growing prescription drug classes in the country.
The drugs work. The STEP trials for semaglutide (Wegovy) showed average weight loss of 15-17% over 68 weeks. The SURMOUNT trials for tirzepatide (Zepbound) pushed that to 20-22%. For men carrying 40, 60, 80 extra pounds, men who've tried everything else, these numbers represent a reset button that didn't exist five years ago.
But weight loss isn't a single variable. For men specifically, what you lose matters as much as how much you lose. The clinical data shows a consistent pattern: men on GLP-1 therapies lose more lean body mass than women, experience different hormonal responses, and face metabolic consequences that don't show up on the scale. This article exists because the men taking these drugs, or thinking about it, deserve to know what the tradeoffs actually are, and what protects against them.
What are GLP-1 drugs, and why do three generations exist?
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It signals satiety, slows gastric emptying, and helps regulate blood sugar. The pharmaceutical versions, semaglutide (Ozempic/Wegovy), liraglutide (Saxenda), dulaglutide (Trujicity), are synthetic analogs that amplify this signaling pathway. You eat less because you feel full faster and longer.
Second-generation drugs like tirzepatide (Mounjaro/Zepbound) add a second mechanism: GIP (glucose-dependent insulinotropic polypeptide) receptor agonism. Dual agonists produce more weight loss than GLP-1 alone, likely through enhanced insulin sensitivity and fat metabolism.
Third-generation candidates like retatrutide, currently in Phase 3 trials, add glucagon receptor agonism. Triple agonists target energy expenditure more directly. Early trial data suggests 24%+ weight loss over 48 weeks. These aren't available yet, but they're coming, and the pattern is clear: each generation trades greater efficacy for greater systemic impact.
For men, that systemic impact matters. These drugs don't just reduce appetite. They alter nutrient partitioning, change how your body allocates incoming calories between muscle and fat, and shift metabolic priorities in ways that intersect directly with testosterone signaling, muscle protein synthesis, and recovery capacity.
Why men's outcomes look different: lean mass loss and testosterone
The headline number, 15%, 20%, 22% weight loss, obscures a critical detail: body composition. The STEP-1 trial body composition substudy reported that roughly 40% of total weight lost during semaglutide therapy came from lean body mass (muscle, bone, organ tissue), a pattern echoed across subsequent GLP-1 trials. For a man losing 50 pounds, that's 12-20 pounds of muscle gone.
Men start with more lean mass than women, but that's not protective, it's a liability. Male skeletal muscle is more metabolically active, more responsive to calorie restriction, and more vulnerable to catabolism during rapid weight loss. The drugs induce weight loss primarily through calorie deficit (you eat less), and the body doesn't distinguish between "intentional pharmaceutical appetite suppression" and "starvation." It responds the same way: preserve fat stores, burn muscle for gluconeogenesis.
Testosterone trajectories diverge. Some men see testosterone rise as visceral fat drops and insulin sensitivity improves, particularly men starting with metabolic syndrome or obesity-related hypogonadism. But others experience testosterone decline tied to the severity of calorie deficit, the rate of lean mass loss, and the body's downregulation of anabolic signaling under perceived scarcity. The drug doesn't suppress testosterone directly, but the metabolic context it creates, deep deficit, rapid muscle loss, chronic low energy availability, can.
This isn't failure. It's biology. The question isn't whether these tradeoffs exist. It's whether men know they exist, and whether they're doing anything to counteract them.
The editorial position: know what they take, protect what matters
Brookhaven's position on GLP-1 therapies isn't pro or anti. It's informed. These drugs are tools. For some men, they're life-saving tools, reversing Type 2 diabetes, eliminating sleep apnea, dropping cardiovascular risk markers that were headed toward early mortality. For others, they're elective tools chosen for aesthetics or quality-of-life reasons that are entirely valid.
But tools have costs. The cost of GLP-mediated weight loss, for men, is:
- Accelerated muscle loss, more than you'd lose through calorie restriction alone.
- Hormonal volatility, testosterone can rise or fall depending on your starting metabolic state and how aggressively you lose.
- Nutrient absorption challenges, slowed gastric emptying reduces the window for digesting protein, minerals, and fat-soluble vitamins.
- Training adaptation blunting, muscle protein synthesis is compromised when energy availability is chronically low and appetite is pharmacologically suppressed.
The men who do well on these drugs, who come off lean, strong, hormonally stable, aren't the ones who just take the shot and let it ride. They're the ones who treat the drug as part of a system: high-protein intake (1.2-1.6g per pound of goal bodyweight), consistent resistance training (3-4x/week minimum), micronutrient density, and intentional support for testosterone signaling and recovery.
That's where Brookhaven's protocol intersects. The Total Men's Package wasn't designed for GLP-1 users specifically, but it was designed for the exact metabolic context these drugs create: calorie deficit, muscle preservation priority, hormonal optimization under stress, bioavailable nutrition when appetite is suppressed. Men using these drugs need every advantage they can get. Food-derived organ nutrition, adaptogen support for testosterone signaling, and micronutrients optimized for male physiology become non-negotiable.
What comes next: the conversation, not the prescription
This is the first article in a series. We're not here to tell you whether to take these drugs. We're here to tell you what happens when you do, what the research actually shows for men, and what protects you on the other side.
Coming articles will cover: muscle preservation strategies for men on GLP-1s, testosterone monitoring and what to watch for, training modifications that work under appetite suppression, and what happens when you come off, the rebound risk, the metabolic recalibration, and how to exit without losing everything you gained.
The GLP era is here. Six million Americans are already in it. Ten million will be soon. For men, the question isn't whether these drugs work. It's whether you know what they cost, and whether you're willing to pay for protection.
Frequently asked questions
Do GLP-1 drugs like Ozempic lower testosterone in men?
GLP-1 medications don't directly suppress testosterone production, but they create metabolic conditions that can lower testosterone in some men: severe calorie deficit, rapid lean mass loss, and chronic low energy availability. Some men see testosterone rise as visceral fat drops and insulin sensitivity improves, while others experience declines tied to the rate and severity of weight loss. The outcome depends on starting metabolic health, how aggressively you lose weight, and whether you're protecting lean mass through resistance training and adequate protein. Monitoring testosterone before, during, and after GLP-1 therapy is advisable for men over 35.
How much muscle do men typically lose on semaglutide or tirzepatide?
Clinical trial data shows that 25-40% of total weight lost during GLP-1 therapy comes from lean body mass, which includes muscle, bone, and organ tissue. For a man losing 50 pounds, that's 12-20 pounds of muscle. Men lose proportionally more lean mass than women during rapid weight loss because male skeletal muscle is more metabolically active and more vulnerable to catabolism under calorie restriction. This isn't inevitable, high protein intake (1.2-1.6g per pound of goal bodyweight) and consistent resistance training (3-4x per week minimum) significantly reduce lean mass loss, but these interventions must be intentional and sustained throughout treatment.
Should men take supplements while on GLP-1 medications?
Yes, but the focus should be micronutrient density and bioavailability, not random supplementation. GLP-1 drugs slow gastric emptying, which reduces the absorption window for protein, minerals, and fat-soluble vitamins. Men on these medications need higher nutrient density per calorie consumed, with emphasis on zinc, magnesium, vitamin D, and bioavailable forms of B vitamins. Food-derived nutrition, like grass-fed beef organ complexes, provides cofactors and nutrient matrices that isolated vitamins lack. Adaptogen support for testosterone signaling (tongkat ali, shilajit, fenugreek) becomes more relevant when appetite suppression limits overall food intake and calorie deficit stresses hormonal systems.
What's the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?
Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist; Ozempic is FDA-approved for Type 2 diabetes at lower doses (0.5-2mg), while Wegovy is approved for weight management at higher doses (2.4mg). Mounjaro and Zepbound both contain tirzepatide, a dual GLP-1/GIP receptor agonist; Mounjaro is approved for diabetes, Zepbound for weight loss. Tirzepatide produces more weight loss than semaglutide (20-22% vs 15-17% in trials) due to the added GIP mechanism, but also has broader metabolic effects. All four drugs work by reducing appetite and slowing gastric emptying; the primary differences are mechanism (single vs dual agonist) and FDA-approved indication.
Can you build muscle while taking GLP-1 drugs?
Building significant muscle while on GLP-1 therapy is difficult but not impossible, and depends entirely on whether you're in a true calorie deficit or maintaining/surplus. Most men using these drugs are losing weight, which means calorie deficit, which means muscle protein synthesis is compromised. You can preserve existing muscle and potentially gain small amounts of strength through neuromuscular adaptation, but hypertrophy requires energy surplus and appetite that these drugs pharmacologically suppress. The realistic goal for most men during active GLP-1 treatment is muscle preservation, not growth. Muscle building becomes viable after weight stabilization or during structured refeeds, but requires deliberate training programming and aggressive protein intake (1.4-1.6g per pound of goal bodyweight minimum).
How long do men typically stay on GLP-1 medications?
Clinical trial durations range from 68 weeks (STEP trials) to 72 weeks (SURMOUNT trials), but real-world use varies widely. Some men use GLP-1 drugs for 6-12 months to achieve target weight loss, then discontinue; others remain on maintenance doses indefinitely to prevent regain. The challenge is that discontinuation often leads to weight regain, studies show 50-70% of lost weight returns within 12 months of stopping, because the drug doesn't reprogram metabolism or appetite regulation. Men who successfully maintain weight loss after stopping tend to have built sustainable nutrition and training habits during treatment, addressed underlying metabolic dysfunction, and transitioned to a lifestyle that supports the new body composition without pharmaceutical appetite suppression.
Sources
- KFF Health Tracking Poll (May 2024). The Public's Use and Views of GLP-1 Drugs.
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11):989-1002.
- Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.
- Corona G et al. (2013). Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology, 168(6):829-843.
- FDA, Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.
